699 related articles for article (PubMed ID: 33538113)
1. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
4. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib for osteoarthritis.
Puljak L; Marin A; Vrdoljak D; Markotic F; Utrobicic A; Tugwell P
Cochrane Database Syst Rev; 2017 May; 5(5):CD009865. PubMed ID: 28530031
[TBL] [Abstract][Full Text] [Related]
9. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
[TBL] [Abstract][Full Text] [Related]
10. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
[TBL] [Abstract][Full Text] [Related]
11. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.
Carrino JA; McAlindon TE; Schnitzer TJ; Guermazi A; Hochberg MC; Conaghan PG; Brown MT; Burr A; Fountaine RJ; Pixton GC; Viktrup L; Verburg KM; West CR
Osteoarthritis Cartilage; 2023 Dec; 31(12):1612-1626. PubMed ID: 37652258
[TBL] [Abstract][Full Text] [Related]
12. Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.
Brown MT; Sandroni P; Low PA; Gorson KC; Hunter DJ; Pixton GC; Fountaine RJ; Viktrup L; West CR; Verburg KM
J Neurol Sci; 2022 Mar; 434():120184. PubMed ID: 35217440
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
Miki K; Ohta M; Abe M; Yoshimatsu H; Fujii K; Ebata N; West CR; Brown MT; Pixton G; Isogawa N
Pain Ther; 2022 Sep; 11(3):827-844. PubMed ID: 35538185
[TBL] [Abstract][Full Text] [Related]
14. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials.
Mease P; Kuritzky L; Wright WL; Mallick-Searle T; Fountaine R; Yang R; Sadrarhami M; Faison W; Johnston E; Viktrup L
Curr Med Res Opin; 2022 Nov; 38(11):1909-1922. PubMed ID: 35980115
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study.
Gibofsky A; Hochberg MC; Jaros MJ; Young CL
Curr Med Res Opin; 2014 Sep; 30(9):1883-93. PubMed ID: 25050589
[TBL] [Abstract][Full Text] [Related]
17. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
[TBL] [Abstract][Full Text] [Related]
18. WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee.
Watson M; Brookes ST; Faulkner A; Kirwan J
Cochrane Database Syst Rev; 2007 Jul; 2006(1):CD000142. PubMed ID: 17636601
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials.
Baraf HS; Gloth FM; Barthel HR; Gold MS; Altman RD
Drugs Aging; 2011 Jan; 28(1):27-40. PubMed ID: 21174485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
